PURPOSE: Although microarray technology has been widely adopted by the scientific community, analysis of the ensuing data remains challenging. In this article, we present our experience with a complex design microarray experiment on resistance mechanisms of histone deacetylase inhibitors (HDACI). EXPERIMENTAL DESIGN: To improve our understanding of the underlying mechanism of HDACI resistance in prostate cancer cells, we designed a novel "multiple-loop, double-cube" cDNA microarray experiment. In the experiment of 22 arrays, DU145 and PC3 cells were treated with two different HDACIs (vorinostat and valproic acid) and incubation periods (48 and 96 h). Preprocessing included exploratory analyses of the quality of the arrays and intensity-dependent within-array Loess normalization. An ANOVA model was used for inference. The results were validated by Western blot analysis of known treatment targets. RESULTS: Treatment of PC3 and DU145 cells with HDACIs caused 2.8% to 10% (P<0.001) differential expression across conditions; 51% to 73% of these genes were up-regulated and 28% to 49% were down-regulated. The extent of differential expression was associated with cell line (DU145>PC3), HDACI (valproic acid >or= vorinostat), and duration of treatment (96>48 h). We identified known and new treatment targets involved in cell cycle and apoptosis. CONCLUSION: A multiple-loop, double-cube microarray design can be used to identify HDACI-induced changes in gene expression possibly related to drug resistance.
PURPOSE: Although microarray technology has been widely adopted by the scientific community, analysis of the ensuing data remains challenging. In this article, we present our experience with a complex design microarray experiment on resistance mechanisms of histone deacetylase inhibitors (HDACI). EXPERIMENTAL DESIGN: To improve our understanding of the underlying mechanism of HDACI resistance in prostate cancer cells, we designed a novel "multiple-loop, double-cube" cDNA microarray experiment. In the experiment of 22 arrays, DU145 and PC3 cells were treated with two different HDACIs (vorinostat and valproic acid) and incubation periods (48 and 96 h). Preprocessing included exploratory analyses of the quality of the arrays and intensity-dependent within-array Loess normalization. An ANOVA model was used for inference. The results were validated by Western blot analysis of known treatment targets. RESULTS: Treatment of PC3 and DU145 cells with HDACIs caused 2.8% to 10% (P<0.001) differential expression across conditions; 51% to 73% of these genes were up-regulated and 28% to 49% were down-regulated. The extent of differential expression was associated with cell line (DU145>PC3), HDACI (valproic acid >or= vorinostat), and duration of treatment (96>48 h). We identified known and new treatment targets involved in cell cycle and apoptosis. CONCLUSION: A multiple-loop, double-cube microarray design can be used to identify HDACI-induced changes in gene expression possibly related to drug resistance.
Authors: T R Hughes; C J Roberts; H Dai; A R Jones; M R Meyer; D Slade; J Burchard; S Dow; T R Ward; M J Kidd; S H Friend; M J Marton Journal: Nat Genet Date: 2000-07 Impact factor: 38.330
Authors: T R Hughes; M J Marton; A R Jones; C J Roberts; R Stoughton; C D Armour; H A Bennett; E Coffey; H Dai; Y D He; M J Kidd; A M King; M R Meyer; D Slade; P Y Lum; S B Stepaniants; D D Shoemaker; D Gachotte; K Chakraburtty; J Simon; M Bard; S H Friend Journal: Cell Date: 2000-07-07 Impact factor: 41.582
Authors: Robert B Scharpf; Christine A Iacobuzio-Donahue; Julie B Sneddon; Giovanni Parmigiani Journal: Biostatistics Date: 2006-12-12 Impact factor: 5.899
Authors: William Kevin Kelly; Owen A O'Connor; Lee M Krug; Judy H Chiao; Mark Heaney; Tracy Curley; Barbara MacGregore-Cortelli; William Tong; J Paul Secrist; Lawrence Schwartz; Stacy Richardson; Elaina Chu; Semra Olgac; Paul A Marks; Howard Scher; Victoria M Richon Journal: J Clin Oncol Date: 2005-05-16 Impact factor: 44.544
Authors: Tony Reid; Frank Valone; William Lipera; David Irwin; Warren Paroly; Ron Natale; Sunil Sreedharan; Harold Keer; Bert Lum; Frank Scappaticci; Anish Bhatnagar Journal: Lung Cancer Date: 2004-09 Impact factor: 5.705
Authors: Michel D Wissing; Janet Mendonca; Madeleine S Q Kortenhorst; Nadine S Kaelber; Matthew Gonzalez; Eunice Kim; Hans Hammers; Paul J van Diest; Michael A Carducci; Sushant K Kachhap Journal: FASEB J Date: 2013-07-24 Impact factor: 5.191
Authors: Madeleine S Q Kortenhorst; Michel D Wissing; Ronald Rodríguez; Sushant K Kachhap; Judith J M Jans; Petra Van der Groep; Henk M W Verheul; Anuj Gupta; Paul O Aiyetan; Elsken van der Wall; Michael A Carducci; Paul J Van Diest; Luigi Marchionni Journal: Epigenetics Date: 2013-07-19 Impact factor: 4.528
Authors: Sushant K Kachhap; Nadine Rosmus; Spencer J Collis; Madeleine S Q Kortenhorst; Michel D Wissing; Mohammad Hedayati; Shabana Shabbeer; Janet Mendonca; Justin Deangelis; Luigi Marchionni; Jianqing Lin; Naseruddin Höti; Johan W R Nortier; Theodore L DeWeese; Hans Hammers; Michael A Carducci Journal: PLoS One Date: 2010-06-18 Impact factor: 3.240
Authors: Madeleine S Q Kortenhorst; Sumit Isharwal; Paul J van Diest; Wasim H Chowdhury; Cameron Marlow; Michael A Carducci; Ronald Rodriguez; Robert W Veltri Journal: Mol Cancer Ther Date: 2009-04 Impact factor: 6.261
Authors: Laura Shulak; Vladimir Beljanski; Cindy Chiang; Sucharita M Dutta; Julien Van Grevenynghe; S Mehdi Belgnaoui; Thi Lien-Anh Nguyên; Thomas Di Lenardo; O John Semmes; Rongtuan Lin; John Hiscott Journal: J Virol Date: 2013-12-26 Impact factor: 5.103
Authors: Channing J Paller; Michel D Wissing; Janet Mendonca; Anup Sharma; Eugene Kim; Hea-Soo Kim; Madeleine S Q Kortenhorst; Stephanie Gerber; Marc Rosen; Faraz Shaikh; Marianna L Zahurak; Michelle A Rudek; Hans Hammers; Charles M Rudin; Michael A Carducci; Sushant K Kachhap Journal: Cancer Med Date: 2014-07-03 Impact factor: 4.452